EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma

Salih Demir iD, Marie Friederike Bentrop, Alina Hotes, Tanja Schmid, Emilie Indersie, Sophie Branchereau, Christian Vokuhl, Beate Häberle iD, Irene Schmid iD, Stefano Cairo iD, Roland Kappler iD

International Journal of Molecular Sciences · 10.06.2026 · 27 (12) · 5237

DOI: 10.3390/ijms27125237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2026. Verfasst von Salih Demir und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstreet 2a, 80337 Munich, Germany. Hauptthemen laut MEDLINE: Polycomb Repressive Complex 1, Hepatoblastoma, Liver Neoplasms, Antineoplastic Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020 research and innovation program, Bettina Bräu Foundation Munich, Gänseblümchen Association Voerde.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatoblastoma (HB), the most common pediatric liver cancer, exhibits marked variability in therapeutic response despite minimal genetic heterogeneity, implicating epigenetic regulation as a key driver of tumor behavior. Among these, polycomb repressor complexes (PRC) remain poorly explored as therapeutic targets. Integrative analysis of samples from patients with HB and public datasets identified BMI1, a core component of PRC1, as significantly upregulated, with high expression strongly associated with aggressive disease and poor survival. Functional screening of epigenetic inhibitors across 15 HB cell lines revealed BMI1 inhibition as the most effective therapeutic strategy, with strong concordance between in vitro predictions and in vivo responses in patient-derived xenograft (PDX) models. The BMI1 inhibitor PTC596 demonstrated the highest potency, consistently suppressing tumor growth across models. Mechanistically, PTC596 induced BMI1 degradation, reduced histone H2A ubiquitination, impaired microtubule dynamics, and restored intrinsic apoptosis by shifting the BCL2–BAX balance, leading to caspase-3/7 activation. Transcriptomic profiling confirmed apoptosis as the most significantly enriched pathway. In vivo, PTC596 markedly reduced tumor burden and proliferation while inducing pro-apoptotic signaling, without detectable toxicity. Together, these findings establish BMI1 as a critical oncogenic dependency in HB, demonstrate the value of robust preclinical tumor modeling for therapeutic validation, and identify PTC596 as a promising, mechanism-based treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycomb Repressive Complex 1HepatoblastomaLiver NeoplasmsAntineoplastic AgentsHumansAnimalsMiceApoptosisCell Line, TumorXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticCell ProliferationEpigenesis, Genetic

Stichwörter der Autor:innen

BMI1PTC596apoptosishepatoblastomapolycomb repressive complex

Substanzen

Polycomb Repressive Complex 1BMI1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstreet 2a, 80337 Munich, Germany.
  • XenTech, 91000 Evry, France.
  • Bicêtre Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
  • Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany.
  • Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, 80337 Munich, Germany.
  • Champions Oncology, Rockville, MD 20850, USA.

ORCID-Profile: Salih Demir, Beate Häberle, Irene Schmid, Stefano Cairo, Roland Kappler

Förderung

  • European Union’s Horizon 2020 research and innovation program
  • Bettina Bräu Foundation Munich
  • Gänseblümchen Association Voerde

Zitieren

APA

Demir, S., Bentrop, M. F., Hotes, A., Schmid, T., Indersie, E., Branchereau, S., Vokuhl, C., Häberle, B., Schmid, I., Cairo, S., & Kappler, R. (2026). Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma. International Journal of Molecular Sciences, 27(12), 5237. https://doi.org/10.3390/ijms27125237

Vancouver

Demir S, Bentrop MF, Hotes A, Schmid T, Indersie E, Branchereau S, et al. Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma. International Journal of Molecular Sciences. 2026;27(12):5237. doi:10.3390/ijms27125237

BibTeX
@article{Demir2026,
  author = {Demir, Salih and Bentrop, Marie Friederike and Hotes, Alina and Schmid, Tanja and Indersie, Emilie and Branchereau, Sophie and Vokuhl, Christian and Häberle, Beate and Schmid, Irene and Cairo, Stefano and Kappler, Roland},
  title = {Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5237},
  doi = {10.3390/ijms27125237}
}
Kostenlos starten →